E-CANE: national remote therapeutic education workshops for adolescents and young adults with cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

E-CANE is an observational program delivering remote Therapeutic Patient Education (e-TPE) workshops to adolescents and young adults (AYA) with cancer, coordinated from CHU Nice. Participants are AYA patients followed by one of the 27 French AYA coordinating nurses and must meet basic functional and technical criteria to join online sessions. The program builds on TPE methods used in chronic disease care to reinforce self-management, adherence, and psychosocial adaptation during and after cancer treatment. Outcomes focus on patient-reported skills, adherence-related behaviors, and feasibility of delivering education remotely to this age group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with cancer diagnosed for at least one month.
* Patient followed by an AYA Coordinating Nurse in one of the 27 French AYA centres.
* Patient with Life expectancy ≥ 6 months.
* Patient ealth status consistent with program requirements.
* Karnosky index \> 60%.
* Patient who agrees to participate in the program and benefits from social security.
* Patient able to understand, speak and read French.
* Patient with no major cognitive impairment (assessed by the patient's referees).
* Patient with no sensory disability.
* Patient with access to a computer tool (smartphone, tablet, computer) and a WiFi or 4G network.
* Non opposition from patient or their legal representative collected.
* Patient who has signed the Privacy Policy.
* Patient who consented to participate in PTE program.

Exclusion Criteria:

* Patient unable to use informatic tools.
* Known superior cognitive function disorders.
* Progressive psychiatric pathology
* Drug user or alcohol abuse

Where it's running

• Chu Nice
  Nice, Alpes Maritimes, France Recruiting

Study contacts

• Study coordinator: Maryline Poirée
• Email: poiree.m@chu-nice.fr
• Phone: 0492039293

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy

  This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07874308

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients

  The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.

  Recruiting at 2 sites Regional Specialist Hospital in Wroclaw · Wroclaw, Lower Silesian Voivodeship and 1 other locations · NCT07727876

• How environment and biology together predict health, aging, and death

  Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.

  Recruiting Longevity Metrics, Inc. · Boulder, Colorado · NCT07646782

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• TriAdeno and N-803 vaccine in early prostate cancer on active surveillance

  A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07574541

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.